Clopidogrel Bisulfate has 12 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Esomeprazole, Omeprazole, Repaglinide. Patients taking Clopidogrel Bisulfate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 12
- Contraindicated
- 3
- Major
- 6
- Moderate
- 3
Contraindicated (3)
- Clopidogrel Bisulfate + Esomeprazole— Avoid concomitant use. Esomeprazole significantly reduces the antiplatelet activity of clopidogrel bisulfate when given …
- Clopidogrel Bisulfate + Omeprazole— Avoid concomitant use. Omeprazole significantly reduces the antiplatelet activity of clopidogrel bisulfate when given co…
- Clopidogrel Bisulfate + Repaglinide— Clopidogrel increases repaglinide exposure 3.9-5.1 fold. Avoid concomitant use or adjust dose and monitor closely.
Major (6)
- Clopidogrel Bisulfate + Aspirin— Increases risk of gastrointestinal bleeding when coadministered with clopidogrel.
- Clopidogrel Bisulfate + Morphine— Opioid agonist that delays and reduces clopidogrel absorption, decreasing exposure to active metabolites. Consider paren…
- Clopidogrel Bisulfate + Nonsteroidal Anti-Inflammatory Drugs (Nsaids)— Increases risk of gastrointestinal bleeding when coadministered with clopidogrel.
- Clopidogrel Bisulfate + Rifampin— Strong CYP2C19 inducer that increases clopidogrel active metabolite levels and platelet inhibition, potentiating risk of…
- Clopidogrel Bisulfate + Selective Serotonin Reuptake Inhibitors (Ssri)— Increases risk of bleeding when coadministered with clopidogrel.
- Clopidogrel Bisulfate + Warfarin— Coadministration increases bleeding risk due to independent effects on hemostasis, despite no pharmacokinetic interactio…
Moderate (3)
- Clopidogrel Bisulfate + Dexlansoprazole— CYP2C19 inhibitor with less effect on clopidogrel antiplatelet activity compared to omeprazole or esomeprazole.
- Clopidogrel Bisulfate + Lansoprazole— CYP2C19 inhibitor with less effect on clopidogrel antiplatelet activity compared to omeprazole or esomeprazole.
- Clopidogrel Bisulfate + Pantoprazole— CYP2C19 inhibitor with less effect on clopidogrel antiplatelet activity compared to omeprazole or esomeprazole.